Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Nasopharyngeal Carcinoma 3Leukemia, Myeloid, Acute 3Squamous Cell Carcinoma of Head and Neck 2Myelodysplastic Syndromes 2Carcinoma, Non-Small-Cell Lung 2Turcot syndrome 1Tongue Neoplasms 1Thrombocythemia, Essential 1Rhabdoid Tumor 1Rectal Neoplasms 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Nasopharyngeal Neoplasms 1Myeloproliferative Disorders 1Multiple Myeloma 1Lymphoma 1Lung Neoplasms 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Hypopharyngeal Neoplasms 1Head and Neck Neoplasms 1Esophagitis 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1ESCC 1Choroid Plexus Neoplasms 1Central Nervous System Neoplasms 1

Interventions

Induction Chemotherapy 1Immunotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × ESCC × Induction Chemotherapy × Clear all
NCT07015489 2025-06-11

Concurrent Radiotherapy Following Induction Chemoimmunotherapy for Locally Advanced Esophageal Cancer

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Completed
44 enrolled

ESCC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡